Back to search

Article

Targeting senescent cells by dasatinib and quercetin ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration.

2022-04-06

Abstract excerpt

Clinical therapies developed for estrogen-deficiency-driven postmenopausal osteoporosis (PMO) and related diseases, such as bone degeneration, show multiple adverse effects nowadays. Targeting senescent cells (SnCs) and the consequent senescence-associated secretory phenotype (SASP) with a combination of dasatinib and quercetin (DQ) is a recently developed novel therapy for multiple age-related diseases. Herein, w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eb1d2681-8c24-5381-a71b-e35f5005dd0d
DOI
10.21203/rs.3.rs-1444778/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting senescent cells by dasatinib and quercetin ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration.DOI 10.21203/rs.3.rs-1444778/v1
Select a neighboring publication to make it the new centre.